U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07366528) titled 'Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer' on Jan. 16.
Brief Summary: This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
Study Start Date: Dec. 15, 2025
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer (GC)
Adjuvant Chemotherapy
Stage 3 Cancer
Docetaxel
Oxaliplatin
Intervention:
DRUG: Oxaliplatin plus S-1
SOX group: eight 3-w...